{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:35:50Z","timestamp":1793136950070,"version":"4.5.0"},"reference-count":5,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jaad.2026.04.2020","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:48:33Z","timestamp":1783061313000},"page":"e465-e466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sexual function is missing from the adverse-effect map of GLP-1 receptor agonists in dermatology"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5783-6875","authenticated-orcid":false,"given":"Franco","family":"Grimolizzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2026.04.2020_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2025.12.116","article-title":"JAAD CME Part 2: clinical evidence and safety considerations for GLP-1 receptor agonists in dermatology","author":"Narla","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2026.04.2020_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-086886","article-title":"Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study","volume":"392","author":"Cai","year":"2026","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.jaad.2026.04.2020_bib3","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41443-025-01061-2","article-title":"Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data","volume":"37","author":"Pourabhari Langroudi","year":"2025","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.jaad.2026.04.2020_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2026.116085","article-title":"Short- and long-acting GLP-1 receptor agonists decrease female sexual behaviors in experienced rodents","volume":"504","author":"Shevchouk","year":"2026","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.jaad.2026.04.2020_bib5","article-title":"Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we do not see it","volume":"14","author":"Gelfand","year":"2025","journal-title":"Obes Pillars"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226030367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226030367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:28:50Z","timestamp":1793136530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226030367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":5,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0190962226030367"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.04.2020","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sexual function is missing from the adverse-effect map of GLP-1 receptor agonists in dermatology","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.04.2020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}